RxDoctor Payments Data

Elizabeth Kline

Family · Altoona, PANPI 1639283989

Payments from drug & device makers

$10,882in general payments, 2019–2025

Across 670 payments — averaging $16.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$3K
  • Abbott$1K
  • AbbVie$666
  • AstraZeneca$632
  • UCB, Inc.$536
  • Lundbeck LLC$463
  • plus $5K from 45 others

What the payments were for

  • Food & beverage$10,882100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,882 in reported general payments places this provider in the 95th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$22,103
Medicare patients
120
Services billed
294

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl218$198,155
Buprenorphine354$97,227
MovantikNaloxegol Oxalate58$41,902
LinzessLinaclotide42$35,842
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,195$25,482
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen934$23,410
ButransBuprenorphine38$20,302
Oxycodone Hcl1,145$19,197
Gabapentin691$13,337
SymproicNaldemedine Tosylate18$10,624
Pregabalin178$6,266
Duloxetine Hcl215$5,377
Morphine Sulfate198$4,889
Tramadol Hcl539$4,187
Baclofen291$3,441

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$65$198,155218 claims
AbbVieLinzess$666$35,84242 claims
Upsher-smith Laboratories LLCTopiramate$18$1,37763 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,717 family providers in Pennsylvania.

Other family in Altoona

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →